Life sciences talent consultancy, the RSA Group, has announced the appointment of Alex Bennett as its new CEO.
Alex comes to RSA with an international track record in senior level life sciences executive search, specialising in Medical Devices and Diagnostics. His most recent global leadership roles have been at CT Partners and DHR, as Managing Partner for their Global Medical Devices and Diagnostics business and for their London office.
Welcoming Alex to the company, RSA Executive Chairman Nick Stephens said: “We’re delighted that Alex is joining our firm. He brings a powerful combination of domain knowledge and a global network that will add value to existing and to new clients. His skills and experience, combined with our distinctive due diligence methodology will drive the next phase of our evolution.”
Alex commented on his new appointment: “I am tremendously excited to be joining RSA as CEO. This promises to be a significant period in the company’s history in which we will expand our expertise and global footprint. Our service will evolve in line with our clients’ needs, cementing our global reputation as the Life Science industry’s leading executive search specialist. Those involved in talent acquisition must evolve to meet clients’ demands for increasingly sophisticated insights and advice as they seek the very best talent. RSA’s approach is forward-looking and we will define that future for our clients, candidates and the industry as a whole.”
Alex, who has already joined RSA, replaces Chris Molloy, who leaves to head up the UK Medicines Discovery Catapult. Chris said: “RSA has a unique vision and service to support our clients in making strategic talent decisions. Alex’s arrival reflects the ambition the firm has to scale, and extend its reach across all sectors of the life sciences and healthcare; drugs, diagnostics, devices, data and services. I look forward to maintaining my many personal and professional links with RSA as it continues to grow.”